Please ensure Javascript is enabled for purposes of website accessibility

3 Can't-Miss Quotes From Phillip Frost Regarding Opko Health's Future

By Todd Campbell – Mar 6, 2016 at 9:19AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Iconic billionaire CEO Phillip Frost thinks the opportunities ahead for his company are big.


Iconic healthcare entrepreneur Phillip Frost is at it again. After serving for years as Teva Pharmaceuticals' chairman, the billionaire healthcare investor is in the top seat at Opko Health (OPK 6.38%), and he's knee-deep transforming it into a diagnostics and biopharma powerhouse. In Opko Health's fourth-quarter earnings conference call, Frost laid out his blueprint for Opko Health's future. Read on to see what Frost says are the key opportunities ahead for this company.

Reshaping prostate cancer testing
"The reimbursement and marketing and sales teams are doing a remarkable job with helping make our 4Kscore test a real contribution to men's health [and] the commercial success it deserves to be," Frost said.

Opko Health won approval to begin marketing its novel prostate cancer screening test in 2014. However, winning reimbursement from payers has been challenging, and the company's 10-person sales team, while making progress, had yet to make significant inroads.

That could be changing, however, now that Opko Health owns Bio-Reference Labs, which has 400 salespeople and existing relationships with payers that could accelerate the adoption among doctorsof the 4Kscore test. So far, Opko Health has trained and set loose 200 of Bio-Reference Labs' salespeople, and the company reports monthly volume for the 4Kscore test is growing at a double digit rate. If that pace keeps up, then 4Kscore could exit 2016 as a much bigger contributor to the company's results than it is today, especially if management can negotiate reimbursement rates that are near its $1,900 target.

New kid on the block
"I'm pleased with the progress of all our development projects and thrilled about the second of our projects hopefully to be approved by the FDA soon, Rayaldee," Frost said.

The FDA is scheduled to issue a go/no-go decision on Opko Health's Rayaldee on March 29, and if the regulator gives Rayaldee a green light, then Opko Health will attempt to carve out sales in a market it values at $12 billion.

Rayaldee is a vitamin D prohormone that boosts the vitamin in patients with chronic kidney disease, reducing the risk of secondary hyperparathyroidism (SHPT). Currently, SHPT is treated with vitamin D supplements and therapies that boost calcium levels in the blood. However, Rayaldee may be safer and more efficacious than those approaches. 


Of course, there's no guarantee that the FDA will approve Rayaldee or that doctors will prescribe it. And since Rayaldee is an entirely new approach, it could be slow going at first as the company educates doctors on Rayaldee's benefits.

Nevertheless, Opko Health expects to launch Rayaldee in the second half of this year with a 25-person sales team, and that means investors should have a pretty good idea of its commercial potential within a year or so.

Entering a competitive market
More from Frost:

Varubi, or rolapitant, was recently approved for our partner Tesaro. Tesaro held their fourth quarter conference call last Thursday and they indicated Varubi represents a $1 billion market opportunity. They also reported significant progress with payers noting that during the first 60 days of launch an estimated 120 million covered lives gained access to Varubi under insurance plans.

Certainly, gaining approval from payers is key to the success of any drug, but access alone doesn't guarantee commercial success. That's because the market for treating chemotherapy-induced nausea and vomiting (CINV) is mature and competitive.

Nevertheless, Opko Health's partner on the drug, Tesaro (NASDAQ: TSRO), thinks Varubi is a "$1 billion market opportunity." The person behind tapping into that opportunity is Tesaro's CEO. Lonnie Moulder. Previously, Moulder successfully developed and commercialized the top-selling CINV drug, Aloxi. If Moulder can catch lightning in the bottle a second time, then Opko Health could benefit handsomely from both sales-based milestones and double-digit royalty revenue.

Tying it together
Frost isn't just Opko Health's CEO: He's also the company's biggest shareholder. He's been steadily increasing his stake in Opko Health as shares have dropped, and he directly or indirectly, via his Frost-Gamma fund, owns 182.3 million shares. Clearly, Frost is confident that he can overcome the challenges facing the company and grow sales to a point that justifies his massive position. Only time will tell if he's right, but Frost's track record means it may be worth buying shares in this stock, too.  

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Opko Health Stock Quote
Opko Health
$1.50 (6.38%) $0.09
Teva Pharmaceutical Industries Stock Quote
Teva Pharmaceutical Industries
$8.77 (1.15%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.